Cargando…

Mild cognitive impairment in Parkinson’s disease: the challenge and the promise

This review addresses the literature surrounding Parkinson’s disease (PD) and mild cognitive impairment (MCI). It discusses the neuropsychological, pharmaceutical, and pathological overlap, the socioeconomic impact of PD and MCI, and the value of recognizing, understanding, and treating MCI in PD. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandez, Hubert H, Crucian, Gregory P, Okun, Michael S, Price, Catherine C, Bowers, Dawn
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2426819/
https://www.ncbi.nlm.nih.gov/pubmed/18568128
_version_ 1782156301905690624
author Fernandez, Hubert H
Crucian, Gregory P
Okun, Michael S
Price, Catherine C
Bowers, Dawn
author_facet Fernandez, Hubert H
Crucian, Gregory P
Okun, Michael S
Price, Catherine C
Bowers, Dawn
author_sort Fernandez, Hubert H
collection PubMed
description This review addresses the literature surrounding Parkinson’s disease (PD) and mild cognitive impairment (MCI). It discusses the neuropsychological, pharmaceutical, and pathological overlap, the socioeconomic impact of PD and MCI, and the value of recognizing, understanding, and treating MCI in PD. It is concluded from this review that MCI in PD does exist and should be considered in clinical and research investigations. Due to the lack of accepted clinical criteria, an inclusive operating definition of MCI in PD is proposed. Research guidelines for studying the presence of MCI in PD and evaluating the efficacy of pharmaceutical interventions are also suggested.
format Text
id pubmed-2426819
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-24268192008-06-20 Mild cognitive impairment in Parkinson’s disease: the challenge and the promise Fernandez, Hubert H Crucian, Gregory P Okun, Michael S Price, Catherine C Bowers, Dawn Neuropsychiatr Dis Treat Review This review addresses the literature surrounding Parkinson’s disease (PD) and mild cognitive impairment (MCI). It discusses the neuropsychological, pharmaceutical, and pathological overlap, the socioeconomic impact of PD and MCI, and the value of recognizing, understanding, and treating MCI in PD. It is concluded from this review that MCI in PD does exist and should be considered in clinical and research investigations. Due to the lack of accepted clinical criteria, an inclusive operating definition of MCI in PD is proposed. Research guidelines for studying the presence of MCI in PD and evaluating the efficacy of pharmaceutical interventions are also suggested. Dove Medical Press 2005-03 /pmc/articles/PMC2426819/ /pubmed/18568128 Text en © 2005 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Fernandez, Hubert H
Crucian, Gregory P
Okun, Michael S
Price, Catherine C
Bowers, Dawn
Mild cognitive impairment in Parkinson’s disease: the challenge and the promise
title Mild cognitive impairment in Parkinson’s disease: the challenge and the promise
title_full Mild cognitive impairment in Parkinson’s disease: the challenge and the promise
title_fullStr Mild cognitive impairment in Parkinson’s disease: the challenge and the promise
title_full_unstemmed Mild cognitive impairment in Parkinson’s disease: the challenge and the promise
title_short Mild cognitive impairment in Parkinson’s disease: the challenge and the promise
title_sort mild cognitive impairment in parkinson’s disease: the challenge and the promise
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2426819/
https://www.ncbi.nlm.nih.gov/pubmed/18568128
work_keys_str_mv AT fernandezhuberth mildcognitiveimpairmentinparkinsonsdiseasethechallengeandthepromise
AT cruciangregoryp mildcognitiveimpairmentinparkinsonsdiseasethechallengeandthepromise
AT okunmichaels mildcognitiveimpairmentinparkinsonsdiseasethechallengeandthepromise
AT pricecatherinec mildcognitiveimpairmentinparkinsonsdiseasethechallengeandthepromise
AT bowersdawn mildcognitiveimpairmentinparkinsonsdiseasethechallengeandthepromise